clinical trial · NCT07549412
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
EMD Serono Research & Development Institute, Inc.·phase3·recruiting·n = 1,020
Metastatic Colorectal CancerPrecemtabart tocentecanBevacizumabTrifluridine/Tipiracil (FTD-TPI)
brief summary
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
started
May 6, 2026
primary completion
Oct 16, 2029
completion
Oct 16, 2029
last updated
Aug 14, 2026
official title
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol